Showing 13 to 24 of 37 results
Pharmaceutical Layoffs Reflect Industry Pressures and Strategic Challenges
Facing financial pressures from natural business cycles and regulatory changes, major pharmaceutical companies like Moderna, Biogen, and Johnson & Johnson are laying off employees, raising concerns about the future of research and development.
Pharmaceutical Layoffs Reflect Industry Pressures and Strategic Challenges
Facing financial pressures from natural business cycles and regulatory changes, major pharmaceutical companies like Moderna, Biogen, and Johnson & Johnson are laying off employees, raising concerns about the future of research and development.
Progress
36% Bias Score
IRS to Lay Off 7,000 Probationary Workers
The IRS plans to lay off roughly 7,000 probationary workers, primarily impacting its compliance department, as part of a Trump administration initiative to cut federal spending; the impact on tax collection services is uncertain.
IRS to Lay Off 7,000 Probationary Workers
The IRS plans to lay off roughly 7,000 probationary workers, primarily impacting its compliance department, as part of a Trump administration initiative to cut federal spending; the impact on tax collection services is uncertain.
Progress
52% Bias Score
IRS Cuts Thousands of Workers Amidst Tax Season
The IRS is cutting thousands of probationary workers as tax season begins, following a Trump administration order. This could significantly impact the agency's ability to process the expected 140 million tax returns, despite recent improvements and increased funding.
IRS Cuts Thousands of Workers Amidst Tax Season
The IRS is cutting thousands of probationary workers as tax season begins, following a Trump administration order. This could significantly impact the agency's ability to process the expected 140 million tax returns, despite recent improvements and increased funding.
Progress
48% Bias Score
Pfizer Q4 Earnings Beat Expectations Amidst Covid Revenue Decline and Cost-Cutting Success
Pfizer's Q4 2024 earnings beat analysts' estimates, reporting adjusted EPS of $0.63 and revenue of $17.76 billion, exceeding expectations due to strong Covid product sales and cost reductions; however, future challenges remain due to the Inflation Reduction Act's impact and market competition.
Pfizer Q4 Earnings Beat Expectations Amidst Covid Revenue Decline and Cost-Cutting Success
Pfizer's Q4 2024 earnings beat analysts' estimates, reporting adjusted EPS of $0.63 and revenue of $17.76 billion, exceeding expectations due to strong Covid product sales and cost reductions; however, future challenges remain due to the Inflation Reduction Act's impact and market competition.
Progress
40% Bias Score
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
Progress
60% Bias Score
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Progress
36% Bias Score
Heat Pumps Gain Traction: Financial Incentives Drive Energy-Efficient Home Upgrades
The 2022 Inflation Reduction Act spurred increased adoption of energy-efficient heat pumps for home water and HVAC systems, offering significant financial incentives and substantial long-term cost savings while improving home safety and health.
Heat Pumps Gain Traction: Financial Incentives Drive Energy-Efficient Home Upgrades
The 2022 Inflation Reduction Act spurred increased adoption of energy-efficient heat pumps for home water and HVAC systems, offering significant financial incentives and substantial long-term cost savings while improving home safety and health.
Progress
40% Bias Score
Russia-Ukraine Conflict: Devastating Economic Repercussions for the EU
The Russia-Ukraine conflict severely impacts the EU economy through increased energy prices, fiscal deficits, and weakened euro, exacerbated by differing approaches to aiding Ukraine and the resulting economic and geopolitical implications for the EU's green transition and industrial competitiveness...
Russia-Ukraine Conflict: Devastating Economic Repercussions for the EU
The Russia-Ukraine conflict severely impacts the EU economy through increased energy prices, fiscal deficits, and weakened euro, exacerbated by differing approaches to aiding Ukraine and the resulting economic and geopolitical implications for the EU's green transition and industrial competitiveness...
Progress
52% Bias Score
IRA's Drug Price Controls Threaten Generic Drug Market
The Inflation Reduction Act's (IRA) price negotiation provision for prescription drugs, while intending to lower costs, risks undermining the generic drug market by reducing profit incentives for generic manufacturers, potentially limiting patient access to affordable medications and decreasing inno...
IRA's Drug Price Controls Threaten Generic Drug Market
The Inflation Reduction Act's (IRA) price negotiation provision for prescription drugs, while intending to lower costs, risks undermining the generic drug market by reducing profit incentives for generic manufacturers, potentially limiting patient access to affordable medications and decreasing inno...
Progress
60% Bias Score
Trump Freezes IRA Funds, Creating Clean Energy Uncertainty
President Trump's executive order freezes funding for the Inflation Reduction Act (IRA), creating uncertainty for clean energy projects and international collaborations; the order's impact on already-awarded funds and tax credits remains unclear, potentially triggering legal battles and affecting in...
Trump Freezes IRA Funds, Creating Clean Energy Uncertainty
President Trump's executive order freezes funding for the Inflation Reduction Act (IRA), creating uncertainty for clean energy projects and international collaborations; the order's impact on already-awarded funds and tax credits remains unclear, potentially triggering legal battles and affecting in...
Progress
48% Bias Score
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Progress
48% Bias Score
Medicare to Negotiate Prices for Ozempic, Wegovy, and 13 Other Drugs
Medicare will negotiate prices for Ozempic, Wegovy, and 13 other drugs, impacting 5.3 million Part D users and $41 billion in drug costs, with negotiated prices effective in 2027.
Medicare to Negotiate Prices for Ozempic, Wegovy, and 13 Other Drugs
Medicare will negotiate prices for Ozempic, Wegovy, and 13 other drugs, impacting 5.3 million Part D users and $41 billion in drug costs, with negotiated prices effective in 2027.
Progress
32% Bias Score
Showing 13 to 24 of 37 results